SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Farmakis Dimitrios)
 

Sökning: WFRF:(Farmakis Dimitrios) > Impact of left vent...

  • Farmakis, DimitriosUniv Cyprus, Cyprus (författare)

Impact of left ventricular ejection fraction phenotypes on healthcare resource utilization in hospitalized heart failure: a secondary analysis of REPORT-HF

  • Artikel/kapitelEngelska2023

Förlag, utgivningsår, omfång ...

  • 2023-03-28
  • WILEY,2023
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:liu-193371
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-193371URI
  • https://doi.org/10.1002/ejhf.2833DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agencies|Novartis Pharma AG
  • Aim Evidence on healthcare resource utilization (HCRU) for hospitalized patients with heart failure (HF) and reduced (HFrEF), mildly reduced (HFmrEF) and preserved (HFpEF) ejection fraction is limited.Methods and results We analysed HCRU in relation to left ventricular ejection fraction (LVEF) phenotypes, clinical features and in-hospital and 12-month outcomes in 16 943 patients hospitalized for HF in a worldwide registry. HFrEF was more prevalent (53%) than HFmrEF (17%) or HFpEF (30%). Patients with HFmrEF and HFpEF were older, more often women, with milder symptoms and more comorbidities, but differences were not pronounced. HCRU was high in all three groups; two or more in- and out-of-hospital services were required by 51%, 49% and 52% of patients with HFrEF, HFmrEF and HFpEF, respectively, and intensive care unit by 41%, 41% and 37%, respectively. Hospitalization length was similar (median, 8 days). Discharge prescription of neurohormonal inhibitors was <80% for each agent in HFrEF and only slightly lower in HFmrEF and HFpEF (74% and 67%, respectively, for beta-blockers). Compared to HFrEF, 12-month all-cause and cardiovascular mortality were lower for HFmrEF (adjusted hazard ratios 0.78 [95% confidence interval 0.59-0.71] and 0.80 [0.70-0.92]) and HFpEF (0.64 [0.59-0.87] and 0.63 [0.56-0.71]); 12-month HF hospitalization was also lower for HFpEF and HFmrEF (21% and 20% vs. 25% for HFrEF). In-hospital mortality, 12-month non-cardiovascular mortality and 12-month all-cause hospitalization were similar among groups.Conclusions In patients hospitalized for HF, overall HCRU was similarly high across LVEF spectrum, reflecting the subtle clinical differences among LVEF phenotypes during hospitalization. Discharge prescription of neurohormonal inhibitors was suboptimal in HFrEF and lower but significant in patients with HFpEF and HFmrEF, who had better long-term cardiovascular outcomes than HFrEF, but similar risk for non-cardiovascular events.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Tromp, JasperNatl Heart Ctr Singapore, Singapore; Duke Natl Univ Singapore, Singapore; Univ Med Ctr Groningen, Netherlands; Natl Univ Singapore, Singapore (författare)
  • Marinaki, SmaragdiNatl & Kapodistrian Univ Athens, Greece (författare)
  • Ouwerkerk, WouterNatl Heart Ctr Singapore, Singapore; Univ Amsterdam, Netherlands (författare)
  • Angermann, Christiane E. E.Univ Hosp Wurzburg, Germany (författare)
  • Bistola, VasilikiNatl & Kapodistrian Univ Athens, Greece (författare)
  • Dahlström, UlfLinköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Kardiologiska kliniken US(Swepub:liu)ulfda85 (författare)
  • Dickstein, KennethUniv Bergen, Norway (författare)
  • Ertl, GeorgNatl Heart Ctr Singapore, Singapore; Univ Amsterdam, Netherlands (författare)
  • Ghadanfar, MathieuM Ghadanfar Consulting Life Sci, Switzerland (författare)
  • Hassanein, MahmoudAlexandria Univ, Egypt (författare)
  • Obergfell, AchimNovartis Pharm AG, Switzerland (författare)
  • Perrone, Sergio V. V.El Cruce Hosp Florencio Varela, Argentina (författare)
  • Polyzogopoulou, EftihiaNatl & Kapodistrian Univ Athens, Greece (författare)
  • Schweizer, AnjaNovartis Pharm AG, Switzerland (författare)
  • Boletis, IoannisDuke Natl Univ Singapore, Singapore (författare)
  • Cleland, John G. F.Univ Glasgow, Scotland; Imperial Coll, England (författare)
  • Collins, Sean P. P.Vanderbilt Univ, TN USA (författare)
  • Lam, Carolyn S. P.Natl Heart Ctr Singapore, Singapore; Duke Natl Univ Singapore, Singapore; Natl Univ Singapore, Singapore (författare)
  • Filippatos, GerasimosNatl & Kapodistrian Univ Athens, Greece; Natl & Kapodistrian Univ Athens, Greece (författare)
  • Univ Cyprus, CyprusNatl Heart Ctr Singapore, Singapore; Duke Natl Univ Singapore, Singapore; Univ Med Ctr Groningen, Netherlands; Natl Univ Singapore, Singapore (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:European Journal of Heart Failure: WILEY25:6, s. 818-8281388-98421879-0844

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy